American Heart Journal
Volume 147, Issue 6 , Pages 993-998 , June 2004

Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the assessment of the safety of a new thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction

  • Peter R Sinnaeve, MD, PhD

      Affiliations

    • Department of Cardiology, University of Leuven, Leuven, Belgium
    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    • Corresponding Author InformationReprint requests: Frans Van de Werf, MD, PhD, Department of Cardiology, Gasthuisberg University Hospital, Herestraat 49, B-3000 Leuven, Belgium.
    • ,
  • John H Alexander, MD

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    • ,
  • Kris Bogaerts

      Affiliations

    • Biostatistical Center, University of Leuven, Leuven, Belgium
    • ,
  • Ann Belmans

      Affiliations

    • Biostatistical Center, University of Leuven, Leuven, Belgium
    • ,
  • Lars Wallentin, MD, PhD

      Affiliations

    • Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
    • ,
  • Paul Armstrong, MD

      Affiliations

    • Department of Cardiology, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Jennifer A.A Adgey, MD

      Affiliations

    • Regional Medical Cardiology Centre, Royal Victoria Hospital, Belfast, United Kingdom
    • ,
  • Michal Tendera, MD

      Affiliations

    • Division of Cardiology, Silesian School of Medicine, Katowice, Poland
    • ,
  • Rafael Diaz, MD

      Affiliations

    • Estudios Cardiologicos Latinoamerica, Instituto Cardiovascular de Rosario, Rosario, Argentina
    • ,
  • Leopoldo Soares-Piegas, MD, PhD

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil
    • ,
  • Alec Vahanian, MD

      Affiliations

    • Department of Cardiology, Bichat Hospital, Paris, France
    • ,
  • Christopher B Granger, MD

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    • ,
  • Frans J Van De Werf, MD, PhD

      Affiliations

    • Department of Cardiology, University of Leuven, Leuven, Belgium

Received 23 June 2003 ,Accepted 16 December 2003.

References 

  1. Lincoff AM, Topol EJ. Illusion of reperfusion (does anyone achieve optimal reperfusion during acute myocardial infarction?). Circulation. 1993;88:1361–1374
  2. Steg PG, Goldberg RJ, Gore JM, et al.  Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol. 2002;90:358–363
  3. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group . Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation. 2000;20:101; 2788–94
  4. Antman EM, Gibson CM, de Lemos JA, et al.  Combination reperfusion therapy with abciximab and reduced dose reteplase (results from TIMI 14: the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators). Eur Heart J. 2000;21:1944–1953
  5. Antman EM, Cooper HA, Gibson CM, et al.  Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction (insights from TIMI 14 and InTIME-II). Eur Heart J. 2002;23:928–933
  6. Antman EM, Louwerenburg HW, Baars HF, et al.  Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction (results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial). Circulation. 2002;105:1642–1649
  7. Ross AM, Molhoek P, Lundergan C, et al.  Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin (second trial of Heparin and Aspirin Reperfusion Therapy (HART II)). Circulation. 2001;104:648–652
  8. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605–13
  9. Simoons M, Krzeminska-Pakula M, Alonso A, et al.  Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction (the AMI-SK study). Eur Heart J. 2002;23:1282
  10. de Lemos JA, Antman EM, Gibson CM, et al.  Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction (observations from the TIMI 14 trial). Circulation. 2000;101:239–243
  11. Simes RJ, Topol EJ, Holmes DR, et al.  Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion (importance of early and complete infarct artery reperfusion. GUSTO-I Investigators). Circulation. 1995;91:1923–1928
  12. Gibson CM, Karha J, Murphy SA, et al.  Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003;42:7–16
  13. Dubois CL, Belmans A, Granger CB, et al.  Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol. 2003;42:1178–1185
  14. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition (the GUSTO V randomised trial). Lancet. 2001;357:1905–1914
  15. Montalescot G, Barragan P, Wittenberg O, et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895–1903
  16. Tcheng JE, Kandzari DE, Grines CL, et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. Circulation 2003;108:1316–23

☆ Guest Editor for this manuscript was Carl J. Pepine, MD, University of Florida College of Medicine, Gainesville, Fla.

PII: S0002-8703(04)00023-7

doi: 10.1016/j.ahj.2003.12.028

American Heart Journal
Volume 147, Issue 6 , Pages 993-998 , June 2004

Article Tools

* Image Usage & Resolution